FDMT Overview

4D Molecular Therapeutics, Inc. is a late-stage biotechnology company advancing durable and disease-targeted therapeutics. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The Company is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The Company's non-core programs include 4D-175, 4D-725, and 4D-310.

Wall Street analysts forecast FDMT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FDMT is29.40 USD with a low forecast of 17.00 USD and a high forecast of 38.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4D Molecular Therapeutics Inc revenue for the last quarter amounts to 14.00K USD, decreased -50.00

4D Molecular Therapeutics Inc. EPS for the last quarter amounts to -0.86 USD, increased 30.30

4D Molecular Therapeutics Inc (FDMT) has 227 emplpoyees as of May 11 2026.

Today FDMT has the market capitalization of 1.08B USD.